In the latest trading session,, 50.33 million Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) shares changed hands as the company’s beta touched 0.29. With the company’s most recent per share price at $1.59 changing hands around $0.27 or 20.45% at last look, the market valuation stands at $12.62M. BCLI’s current price is a discount, trading about -532.08% off its 52-week high of $10.05. The share price had its 52-week low at $0.72, which suggests the last value was 54.72% up since then.
Analysts gave the Brainstorm Cell Therapeutics, Inc (BCLI) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BCLI as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Brainstorm Cell Therapeutics, Inc’s EPS for the current quarter is expected to be -0.44.
Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) trade information
Instantly BCLI is in green as seen in intraday trades today. With action 30.33%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -29.96%, with the 5-day performance at 30.33% in the green. However, in the 30-day time frame, Brainstorm Cell Therapeutics, Inc (NASDAQ:BCLI) is 81.51% up.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 32.00%. The 2025 estimates are for Brainstorm Cell Therapeutics, Inc earnings to increase by 4.33%, but the outlook for the next 5-year period is at 27.78% per year.
BCLI Dividends
Brainstorm Cell Therapeutics, Inc is expected to release its next quarterly earnings report in June.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 2.1212% or 1.51 million shares worth $0.51 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and Fidelity Concord Street Trust-Fidelity Extended Market Index Fund . With 50.72 shares estimated at $80640.0 under it, the former controlled 0.64% of total outstanding shares. On the other hand, Fidelity Concord Street Trust-Fidelity Extended Market Index Fund held about 0.40% of the shares, roughly 31.71 shares worth around $50425.0.
